Zymedi

Dr. Sunghoon Kim, CEO of Zymedi, is attending the Gordon Research Conferences(GRC), a prestigious scientific gathering that has grown from its early meetings in the 1920s to hosting nearly 40,000 participants annually across 395+ conferences worldwide. With a strong tradition of fostering open discussion on cutting-edge research, GRC continues to be a hub for scientific innovation and collaboration. We look forward to engaging discussions and new scientific insights from this renowned conference. #Zymedi #GordonResearchConference #Biotech #Innovation #ScientificResearch

We were honored to host a seminar featuring Professor Dae-Hee Kim from Kangwon National University, who also serves as an advisory board member for Zymedi. The seminar took place on February 13 at POSCO Green Building, Yonsei University International Campus. Dr. Kim delivered an insightful presentation on "The Development of Bispecific Antibodies and Their Current Applications." During the event, Sunghoon Kim, CEO of Zymedi, shared, "Through the KIAT project, we plan to collaborate with Evotec in Germany to develop bispecific antibodies. We hope that today's lecture will greatly contribute to our efforts in developing new drugs utilizing bispecific antibodies." #Zymedi #Biotech #BispecificAntibody #DrugDevelopment #Evotec #KIAT

Zymedi at University Networking Day in Songdo On February 13, the University Networking Day was held at Arirang Hall, Gyeongwonjae Ambassador Incheon. This event aimed to foster collaboration and strengthen exchanges between industry, academia, and research institutions in the bio sector. Dr. Namhoon Kwon, CTO of Zymedi, attended the event and introduced Zymedi, sharing our vision and innovations in biotechnology. We look forward to building strong partnerships and driving impactful advancements in the field. #Zymedi #Networking #BioIndustry #Collaboration #UniversityNetworkingDay

Zymedi is partnering with Evotec, a global leader in drug discovery and development, to develop dual-antibody therapeutics for the treatment of asthma and idiopathic pulmonary fibrosis (IPF). This collaboration will leverage Zymedi's AI-powered antibody platform to pioneer innovative approaches for treating inflammatory and fibrotic diseases. The project has been selected as a Global Industry Technology R&D Initiative under the sponsorship of KIAT (Korea Institute for Advancement of Technology). In partnership with Evotec and Yonsei University Severance Hospital, Zymedi has formed a joint development team, with full-scale research scheduled to begin in 2025. We look forward to advancing this groundbreaking initiative and contributing to the development of life-changing therapies for patients worldwide. article in English: https://lnkd.in/d8CredjA article in Korean: https://lnkd.in/dZKTCxNn #Zymedi #Evotec #AntibodyTherapeutics #AIplatform #Asthma #IPF #KIAT #Collaboration #Innovation

On January 8, 2025, Zymedi and inCerebro proudly signed a Memorandum of Understanding (MOU) to collaborate in the groundbreaking field of quantum computing-based drug discovery. This strategic partnership brings together Zymedi's expertise in drug development and inCerebro's innovative quantum computing technologies. Together, we aim to revolutionize the drug discovery process, accelerating the development of new treatments and addressing unmet medical needs. We are thrilled to embark on this journey and look forward to the transformative potential this collaboration will bring to the pharmaceutical industry. #QuantumComputing #DrugDiscovery #Innovation #Partnership #Zymedi #inCerebro

We recently celebrated Christmas together at Zymedi, sharing thoughtful gifts and creating joyful memories. It was a heartwarming moment of connection and camaraderie, reflecting the spirit of the season. We’re grateful for our amazing team and the opportunity to grow together, not only professionally but also as a community. Here’s to more celebrations and success in the future! Wishing everyone a happy and festive holiday season! #TeamCelebration #ChristmasAtWork #ZymediCulture #Holiday2024

Yesterday, at the 2024 National New Drug Development Project Excellence Presentation & 2025 New Project Briefing hosted by Korea Drug Development Fund (KDDF), Zymedi had the honor of presenting one of the outstanding projects. Our presentation topic, “Clinical Phase 1 Development of ZMA001, a Therapeutic Antibody for Pulmonary Arterial Hypertension that Inhibits Immune Cell Migration,” showcases our commitment to addressing unmet medical needs with innovative approaches. This recognition highlights Zymedi's progress in drug development and our dedication to advancing groundbreaking research. We remain committed to creating new value at the forefront of R&D. A heartfelt thank you to our amazing team and collaborators for their hard work, and to everyone supporting Zymedi’s journey. #Zymedi #DrugDevelopment #KDDF #ExcellencePresentation #PulmonaryArterialHypertension #ClinicalTrials #Innovation #ResearchAndDevelopment

Our story has been featured in HelloDD and Chosun Economy. Zymedi, founded in 2019, is developing ZMA001, a treatment for pulmonary arterial hypertension (PAH) based on research into aminoacyl-tRNA synthetase (ARS). Building on findings that ARS is closely linked to various human diseases, we are currently conducting Phase 1 clinical trials in collaboration with the The National Institutes of Health(NIH). Zymedi is committed to delivering innovative therapeutic options in the bio-healthcare field and contributing to the advancement of global health. We look forward to more collaborations and progress as we shape the future together! 자이메디는 2019년 설립 이후, 아미노아실-tRNA 합성효소(ARS) 연구를 기반으로 폐동맥 고혈압 치료제인 ZMA001을 개발하고 있습니다. ARS가 다양한 인간 질병과 밀접하게 연관되어 있다는 점을 발견한 연구를 바탕으로, 현재 미국 국립보건원(NIH)과 공동으로 ZMA001의 임상 1상을 진행 중입니다. 자이메디는 바이오 헬스케어 분야에서 혁신적인 치료 옵션을 제시하고, 이를 통해 인류의 건강에 기여하기 위해 지속적으로 노력하고 있습니다. 더 많은 협력과 발전을 통해 미래를 함께 만들어가길 기대합니다! [HelloDD: https://lnkd.in/eAK4ktHA Chosun Economy:https://lnkd.in/eJBhWsqh] [헬로디디 기사 원문: https://lnkd.in/eAK4ktHA 조선경제 기사 원문: https://lnkd.in/eJBhWsqh] #Biotechnology #HealthcareInnovation #GlobalHealth #Zymedi #Healthcare

Zymedi has been honored with a certificate of appointment from KIAT (Korea Institute for Advancement of Technology) during the 2024 Industrial Technology R&D Grand Exhibition, hosted by the Ministry of Trade, Industry, and Energy of Korea and organized by the Korea Planning & Evaluation Institute of Industrial Technology (KEIT). We are incredibly grateful for this recognition and look forward to contributing to the advancement of industrial technology. The 2024 Industrial Technology R&D Grand Exhibition will be held from Wednesday, November 27 to Friday, November 29 at COEX Hall B. #RnD #Zymedi #KIAT #COEX #exhibition

We are thrilled to share that Dr. Sunghoon Kim, CEO of Zymedi, recently participated as a speaker at the prestigious tRNA Conference, held in Kanazawa, Japan, from November 18 to 22. Dr. Kim delivered an insightful presentation. His talk shed light on groundbreaking advancements in leveraging tRNA synthetase as a therapeutic target, offering new hope for tackling inflammatory and fibrotic conditions. We are proud to contribute to the global dialogue on innovative biopharmaceutical solutions. #tRNA #tRNAconference #Biotechnology #Inflammation #Fibrosis #Innovation #Zymedi